Canada markets closed

Intellia Therapeutics, Inc. (NTLA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
46.12+0.32 (+0.70%)
At close: 04:00PM EST
45.88 -0.24 (-0.52%)
After hours: 07:53PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close45.80
Open44.93
Bid45.60 x 1000
Ask45.88 x 1000
Day's Range44.00 - 47.18
52 Week Range37.08 - 130.33
Volume2,832,113
Avg. Volume1,076,208
Market Cap3.629B
Beta (5Y Monthly)1.83
PE Ratio (TTM)N/A
EPS (TTM)-5.06
Earnings DateFeb 22, 2023 - Feb 27, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est110.65
  • GlobeNewswire

    Intellia Therapeutics Announces Pricing of Public Offering of Common Stock

    CAMBRIDGE, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, announced today the pricing of an underwritten public offering of 6,550,219 shares of its common stock at a public offering price of $45.80 per share. Intellia also granted the underwriter a 30-day option to purchase up to an additional 982,532 shares of its common

  • GlobeNewswire

    Intellia Therapeutics Announces Proposed Public Offering of Common Stock

    CAMBRIDGE, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today announced that it has commenced an underwritten public offering of $250 million of shares of its common stock. Intellia also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock o

  • GlobeNewswire

    Intellia Therapeutics Presents New Interim Data from First-in-Human Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the American College of Allergy, Asthma & Immunology 2022 Annual Scientific Meeting

    Robust reductions in plasma kallikrein levels and HAE attack rates observed at all doses testedAll patients treated in the 25 mg and 75 mg cohorts have an ongoing attack-free interval through latest follow-up First three patients treated have an ongoing attack-free interval of 5.5 – 10.6 months after a single dose of NTLA-2002 NTLA-2002 was generally well-tolerated at all dose levels Intellia to host investor event to discuss updated data from Phase 1/2 study of NTLA-2002, its second systemicall